AstraZeneca Imjudo (tremelimumab) — Established RoW YoY CER by Quarter

Name: AstraZeneca Imjudo (tremelimumab) — Established RoW YoY CER by Quarter (AZN)
Creator: AstraZeneca

Imjudo (tremelimumab) — Established RoW YoY CER (%) (%)

Quarterly Annual

AstraZeneca Imjudo (tremelimumab) — Established RoW YoY CER: -16.0% in Q2 2026, down 12.0 pts from a year earlier.

Latest, Q2 2026

-16.0%

Period ended Jun 30, 2026

Change on a year earlier

-12.0 pts

-4.0% in Q2 2025

History

9 quarters

Since Q2 2024

Sources

Documents cited below

Where the Q2 2026 figure comes from

“|| Imjudo | | 83 | | ( 7 ) | | ( 7 ) | | 51 | | ( 11 ) | | 7 | | ( 3 ) | | ( 3 ) | | 14 | | 25 | | 20 | | 11 | | ( 21 ) | | ( 16 )”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Imjudo (tremelimumab) — Established RoW YoY CER (%) (%)	Year on year	Source
Q2 2026	Jun 30, 2026	-16.0%	-12.0 pts	Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026	Mar 31, 2026	-22.0%	-23.0 pts	Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025	Dec 31, 2025	-18.0%	-26.0 pts	Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025	Sep 30, 2025	-16.0%	-6.0 pts	Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025	Jun 30, 2025	-4.0%	+26.0 pts	Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025	Mar 31, 2025	1.0%	–	Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024	Dec 31, 2024	8.0%	–	Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024	Sep 30, 2024	-10.0%	–	Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024	Jun 30, 2024	-30.0%	–	Form 6-K FY2024Q2 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Imjudo (tremelimumab) — Established RoW YoY CER (%), quarterly Q2 2024–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-imjudo-erow-cer-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.